We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
CD‐sACE2 inclusion compounds: An effective treatment for coronavirus disease 2019 (COVID‐19).
- Authors
Sun, Pengfei; Lu, Xiaosheng; Xu, Chao; Wang, Yanjin; Sun, Wenjuan; Xi, Jianing
- Abstract
Coronaviruses are common human viruses and include the severe acute respiratory syndrome coronavirus (SARS‐CoV), the middle east respiratory syndrome coronavirus and the SARS‐CoV‐2. Coronaviruses mainly bind to transmembrane receptor proteins on the human cell membrane through spike proteins (S‐proteins), thus releasing the RNA of the virus into the interior of the host cell to cause an infection. In this article, we discuss the mechanism and production of cyclodextrin‐soluble angiotensin‐converting enzyme 2 (CD‐sACE2) inclusion compounds in the treatment of SARS‐CoV‐2 infections by blocking S‐proteins. On the basis of the current research evidence, we believe that CD‐sACE2 inclusion compounds have the potential to treat COVID‐19. We hope that our article can provide a theoretical basis for later experiments. Highlights: At present, there are no available drugs or vaccines that can treat or prevent coronavirus disease 2019 (COVID‐19) effectively. We introduce the mechanisms and drug fabrication methods of cyclodextrin‐soluble angiotensin‐converting enzyme 2 (CD‐sACE2) inclusion compounds for the treatment of COVID‐19. It is believed that CD‐sACE2 inclusion compounds can effectively treat COVID‐19.
- Subjects
COVID-19; SARS virus; MERS coronavirus; INCLUSION compounds; THERAPEUTICS
- Publication
Journal of Medical Virology, 2020, Vol 92, Issue 10, p1721
- ISSN
0146-6615
- Publication type
Article
- DOI
10.1002/jmv.25804